Prevalence of piperacillin/tazobactam resistance in invasive Haemophilus influenzae in Germany
JAC-Antimicrobial Resistance · 28.12.2023 · 6 (1)
DOI: 10.1093/jacamr/dlad148 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 28.12.2023. Verfasst von Helene Duske und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Hygiene and Microbiology, University of Würzburg, Josef-Schneider-Str. 2/E1, 97080, Würzburg, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Robert Koch-Institute, Federal Ministry of Health.
Abstract (Originalsprache)
Background
Haemophilus influenzae (Hi) is a Gram-negative bacterium that may cause sepsis or meningitis, treatment of which mainly includes β-lactam antibiotics. Since 2019 EUCAST breakpoints for piperacillin/tazobactam have been available. Little is known about the prevalence and mechanisms of piperacillin/tazobactam resistance in Hi.
Objectives
To provide reliable prevalence data for piperacillin/tazobactam resistance in Hi in Germany, to evaluate different antibiotic susceptibility testing methods and to examine possible resistance mechanisms.
Methods
According to EUCAST breakpoints, the MIC for piperacillin/tazobactam resistance is >0.25 mg/L. All invasive Hi in Germany from 2019 were examined by gradient agar diffusion (GAD) for piperacillin/tazobactam susceptibility. Piperacillin/tazobactam broth microdilution (BMD), piperacillin GAD on tazobactam-containing agar [piperacillin GAD on Mueller–Hinton agar with horse blood (MH-F)/tazobactam) and piperacillin/tazobactam agar dilution (AD) were used for confirmation. Phenotypic testing was complemented by ftsI sequencing.
Results
Piperacillin/tazobactam GAD resulted in 2.9% (21/726) resistant Hi. BMD did not confirm piperacillin/tazobactam resistance. Two strains were found resistant by AD, of which one was also resistant using piperacillin GAD on MH-F/tazobactam. Overall, we found two strains with a piperacillin/tazobactam MIC >0.25 mg/L in at least two different tests (0.3%). Both were β-lactamase-producing amoxicillin/clavulanate-resistant with PBP3 mutations characterized as group III-like+. Relevant PBP3 mutations occurred in six strains without phenotypic piperacillin/tazobactam resistance. These mutations suggest a reduced efficacy of β-lactam antibiotics in these isolates.
Conclusions
Piperacillin/tazobactam resistance prevalence in invasive Hi is low in Germany. Reduced susceptibility was correlated with PBP3 mutations, in particular with group III mutations.
Autor:innen und Institutionen
- Institute for Hygiene and Microbiology, University of Würzburg, Josef-Schneider-Str. 2/E1, 97080, Würzburg, Germany.
- Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Josef-Schneider-Str. 2/E1, 97080, Würzburg, Germany.
ORCID-Profile: Thiên-Trí Lâm
Förderung
- Robert Koch-Institute
- Federal Ministry of Health
Zitieren
APA
Duske, H., Claus, H., Krone, M., & Lâm, T. T. (2023). Prevalence of piperacillin/tazobactam resistance in invasive Haemophilus influenzae in Germany. JAC-Antimicrobial Resistance, 6(1). https://doi.org/10.1093/jacamr/dlad148
Vancouver
Duske H, Claus H, Krone M, Lâm TT. Prevalence of piperacillin/tazobactam resistance in invasive Haemophilus influenzae in Germany. JAC-Antimicrobial Resistance. 2023;6(1). doi:10.1093/jacamr/dlad148
BibTeX
@article{Duske2023,
author = {Duske, Helene and Claus, Heike and Krone, Manuel and Lâm, Thiên-Trí},
title = {Prevalence of piperacillin/tazobactam resistance in invasive Haemophilus influenzae in Germany},
journal = {JAC-Antimicrobial Resistance},
year = {2023},
volume = {6},
number = {1},
doi = {10.1093/jacamr/dlad148}
}
EUVIMED